News Conference News ACC 2017 SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients Todd Neale March 17, 2017
News Conference News ACC 2017 ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More Shelley Wood March 10, 2017
News Opinion Editor's Corner ACC 2016 Hot or Not, This Year’s Trials Offer Food for Thought: My Takeaways From ACC 2016 Shelley Wood April 13, 2016
News Conference News ACC 2016 Hints of What’s to Come in New Coronary Revascularization AUC Caitlin E. Cox April 12, 2016
News Conference News ACC 2016 Valve Hemodynamic Deterioration Post-TAVR Is Rare, Not Linked With Adverse Cardiovascular Outcomes Michael O'Riordan April 07, 2016
News Conference News ACC 2016 Self-Expanding Transcatheter Valve Maintains Advantage Over Surgery at 3 Years in High-Risk Elderly Patients L.A. McKeown April 04, 2016
News Conference News ACC 2016 Meta-analysis Delves Into Bivalirudin Versus Heparin Debate in Primary PCI Yael L. Maxwell April 04, 2016
News Conference News ACC 2016 TAVR Mortality Declines as Volumes Increase: So How Many US Centers Are Enough? Shelley Wood April 03, 2016
News Conference News ACC 2016 Sapien 3 Superior to Surgery Among Intermediate-Risk Patients in Observational Trial Yael L. Maxwell April 03, 2016
News Conference News ACC 2016 When Chosen Wisely, 90-Year-Olds Do Well After TAVR Caitlin E. Cox April 02, 2016
News Conference News ACC 2016 TAVR With Sapien XT Noninferior to Surgery in Intermediate-Risk Patients, With a Win for Transfemoral Shelley Wood April 02, 2016
Presentation ACC 2016 SAPIEN 3 Transcatheter Aortic Valve Replacement Compared with Surgery in Intermediate-Risk Patients: A Propensity Score Analysis Presenter: Vinod Thourani April 01, 2016
News Conference News ACC 2015 ACC-i2 2015: Strategies to Enhance PCI Results, TAVR Highlighted Todd Neale March 20, 2015
News Conference News ACC 2015 DEFLECT III: TAVR Neuroprotection Device Safely Reduces Lesion Volume Yael L. Maxwell March 16, 2015
News Conference News ACC 2015 Thirty-day Outcomes with Sapien 3 Lowest Seen with Balloon-Expandable TAVR Yael L. Maxwell March 15, 2015
News Conference News ACC 2015 Follow-up TAVR Studies Reassure About Valve Durability, Outcomes Todd Neale March 15, 2015
Presentation ACC 2015 Clinical and Echocardiographic Outcomes at 30 Days with the SAPIEN 3 TAVR System in Inoperable, High-Risk and Intermediate-Risk AS Patients Presenter: Susheel K. Kodali March 15, 2015
News Conference News ACC 2014 ACC/i2 2014: Cardiologists Carefully Consider TAVR, Renal Denervation Yael L. Maxwell April 03, 2014